(Oslo , 22end ofMarch 2024 )Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter inNorway , that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Board ofMedistim ASA has approved the Financial Statements for 2023. The Financial Statements are without changes from the preliminary Financial Statements published on the 29th ofFebruary 2024 . The annual report for 2023 is now available. The Annual General Meeting will be held on 24th ofApril 2024 . AboutMedistim :Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment and continues to invest in new product development.Medistim has wholly owned subsidiaries with sales organizations in theUSA ,Germany ,UK ,Spain ,Denmark ,Canada ,China ,Sweden andNorway , in addition to the about 60 distributors inEurope ,Asia ,Middle East ,Africa , andSouth America . For more information, visit theMedistim home page: www.Medistim.com This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12). For more information, contact: President and CEO,Kari E. Krogstad ,Medistim ASA Tel: + 47 918 38 110 Email: kari.krogstad@medistim.com CFO,Thomas Jakobsen ,Medistim ASA Tel: + 47 906 59 940 Email: thomas.jakobsen@medistim.com
Click here for more information
© Oslo Bors ASA, source